Alkermes plc reported earnings per share of $0.00, exceeding a consensus estimate of $-0.02. Despite a strong year-to-date growth of 78.1% in share value, the stock fell 4.53% following the quarterly update, illustrating investor caution amidst ongoing market fluctuations and insider activity.

Key Highlights

  • Alkermes reported earnings per share of $0.00 for Q2 2026, beating expectations of $-0.02.
  • Total revenue surged to $496 million, up from $390.7 million in the previous year.
  • The company’s market capitalization stands at approximately $8.8 billion, reflective of its strong performance.
  • Alkermes shares have risen 78.1% year-to-date, although they are down 8.6% in the past month.

Earnings Performance

Alkermes plc (NASDAQ: ALKS) announced its second-quarter earnings today, reporting a net earnings per share (EPS) of $0.00, which outperformed analysts' expectations of $-0.02. For the quarter ending June 30, 2026, this stable EPS figure comes as a note of relief amid cautious market sentiments. Revenue for the quarter reached $496 million, a significant increase from $390.7 million in Q2 2025.

This rise in revenue was largely driven by strong sales across its proprietary products, indicating a strong product pipeline amid competitive pressures. Investors may focus on this positive trend, which bodes well for the company's ongoing operational strategies, especially as it navigates challenging market conditions.

Revenue Breakdown

Alkermes benefited from diversified revenue streams, with total proprietary net sales amounting to $411.7 million, a sharp increase from $307.2 million reported a year earlier. The performance of individual products was notable, with VIVITROL® generating $124.5 million in sales, slightly up from $121.7 million, and ARISTADA® contributing $96.7 million, though down from $101.3 million. New entrant LUMRYZ® also performed impressively, generating $96.6 million.

Additionally, manufacturing and royalty revenues were consistent at $84.3 million, up from $83.4 million. Alkermes is also poised to benefit from its acquisition of Avadel, which is expected to positively impact financial figures moving forward. This diverse revenue stream adds a cushion against potential downturns, enhancing investor confidence.

Stock Performance Insights

Despite the positive financial metrics, shares of Alkermes have declined today. Year-to-date, stocks have increased by an impressive 78.1%, although they have seen a decline of 8.6% over the past month. The current market capitalization stands at roughly $8.8 billion.

While the increasing revenues demonstrate solid growth, investors may be reacting to broader market uncertainties and recent insider selling activity. VP of Finance sold $687,007 of stock, which may have contributed to some investor caution in the marketplace. The juxtaposition of strong yearly gains against current stock performance highlights a potentially tumultuous investor sentiment.

Future Catalysts to Monitor

Looking ahead, the company’s financial expectations for the full year remain optimistic. Alkermes expects to generate total revenues between $1.730 billion and $1.840 billion, maintaining guidance for research and development and selling expenses. The firm is focused on capturing additional market share with LUMRYZ® and reinforcing the value proposition of its product portfolio.

Investors should keep an eye on updates surrounding LUMRYZ® following its strong early performance and the expected impact of the Avadel acquisition. These developments will be illustrated in upcoming financial disclosures, with the next key catalyst being the Q2 2026 earnings call later this year.

Peers Moving on This News

  • Prothena Corporation PLC (PRTA) down 2.2%
  • Amarin Corporation PLC (AMRN) up 0.4%

Analysis based on the Form 8-K filed 28 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.